Therefore, research on the treatment of dyslipidemia and atherosclerosis with angiopoietin-like 3 and Angptl4-related antibodies has also emerged [39], although such treatment has not yet been widely used in clinical practice. The gene discussed is ANGPTL4; the disease is metabolic syndrome.